Overview

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Gilead Sciences
Sierra Oncology, Inc.

Treatments:

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide